Breast cancer vaccines: promise for the future or pipe dream?
/in Breast Cancer, International Publications /von 2007-10-15 / Cancer 2007 Oct;110(8):1677-86Numerical and functional defects of blood dendritic cells in early- and late-stage breast cancer
/in Breast Cancer, Dendritic Cells, International Publications /von 2007-10-09 / Br. J. Cancer 2007 Nov;97(9):1251-9An immunotherapy approach with dendritic cells genetically modified to express the tumor-associated antigen, HER2
/in Breast Cancer, International Publications /von 2007-09-05 / Cancer Immunol. Immunother. 2008 May;57(5):611-22Dendritic cell vaccination
/in Breast Cancer, Colorectal Cancer, Hypernephroma, International Publications, Malignant Melanoma, Prostate Cancer /von 2007-08-01 / Expert Rev Vaccines 2007 Aug;6(4):617-33A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model
/in Breast Cancer, Dendritic Cells, International Publications /von 2007-08-01 / Cancer Res. 2007 Aug;67(15):7477-86Benefits of superficial hyperthermia treatment planning: five case studies
/in Breast Cancer, Hyperthermia, International Publications, Malignant Melanoma /von 2007-08-01 / Int J Hyperthermia 2007 Aug;23(5):417-29Development of vaccines for high-risk ductal carcinoma in situ of the breast
/in Breast Cancer, International Publications /von 2007-07-15 / Cancer Res. 2007 Jul;67(14):6531-4Antigen loading of dendritic cells with apoptotic tumor cell-preparations is superior to that using necrotic cells or tumor lysates
/in Breast Cancer, International Publications /von 2007-07-01 / Anticancer Res. 2007 Jul-Aug;27(4B):2121-9Reversing adriamycin resistance of human breast cancer cells by hyperthermia combined with Interferon alpha and Verapamil
/in Breast Cancer, Hyperthermia, International Publications /von 2007-06-01 / J. Exp. Clin. Cancer Res. 2007 Jun;26(2):201-7
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
- Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
- Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution